The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
After years trying to rebuild its reputation following the scandal over blood doping, the sport is having to face up to another problem.
In the hours following the incident, journalists Can Dundar and Erdem Gul were found guilty in their trial for revealing state secrets.
After a wintry end to last week, a fast track to summer